Koninklijke DSM (OTCMKTS:RDSMY) has received a consensus recommendation of “Buy” from the six analysts that are presently covering the stock, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $27.00.
RDSMY has been the subject of a number of research analyst reports. Zacks Investment Research lowered shares of Koninklijke DSM from a “buy” rating to a “hold” rating in a report on Tuesday, September 26th. Deutsche Bank upgraded shares of Koninklijke DSM from a “hold” rating to a “buy” rating in a report on Friday, December 1st. Finally, ValuEngine lowered shares of Koninklijke DSM from a “buy” rating to a “hold” rating in a report on Friday, December 1st.
Koninklijke DSM (RDSMY) traded up $0.41 during trading on Friday, hitting $25.88. 27,671 shares of the stock traded hands, compared to its average volume of 35,326. The company has a market cap of $18,484.09, a price-to-earnings ratio of 31.84, a PEG ratio of 2.80 and a beta of 1.26. The company has a quick ratio of 1.54, a current ratio of 2.18 and a debt-to-equity ratio of 0.37. Koninklijke DSM has a 12-month low of $15.54 and a 12-month high of $25.60.
About Koninklijke DSM
Koninklijke DSM N.V. (Royal DSM) is a global science-based company, engaged in offering health, nutrition and materials. The Company’s segments include Nutrition, Performance Materials, Innovation Center and Corporate Activities. Its Nutrition segment includes DSM Nutritional Products and DSM Food Specialties.
Receive News & Ratings for Koninklijke DSM Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Koninklijke DSM and related companies with MarketBeat.com's FREE daily email newsletter.